Metrics
201,384 Downloads
Contact Share
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

21 to 30 of 2,476 Results
Vardarli_Suppl. Table 4.pdf
Vardarli_Suppl. Table 4.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 257.8 KB - MD5: d6acaa2141ff4cf50ded0d6820579aea
Suppl. Table 4. Frequencies of various parameters in included trials, n= 80 trials.
Vardarli_Suppl. Table 3.xlsx
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
MS Excel Spreadsheet - 116.7 KB - MD5: 7b97c14d958dffb9cb3347b48fd10fba
Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...
Vardarli_Suppl. Table 2.pdf
Vardarli_Suppl. Table 2.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 363.9 KB - MD5: 7c1640658f8d06736e3dad712a927841
Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.
Vardarli_Suppl. Table 12.pdf
Vardarli_Suppl. Table 12.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 219.2 KB - MD5: f9d8e1df71b9731cc42906df4abab368
Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 11.pdf
Vardarli_Suppl. Table 11.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 216.4 KB - MD5: 37c1389d7ef9b12de77e87300a627604
Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 10.pdf
Vardarli_Suppl. Table 10.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 219.1 KB - MD5: b0d44cc6d4f377511600f93c84adb67c
Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 1.pdf
Vardarli_Suppl. Table 1.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 625.1 KB - MD5: 591d49eda306f69d5fd24a059d714ccc
Suppl. Table 1. Checklist according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monoth...
Vardarli_Suppl Fig 9.pdf
Vardarli_Suppl Fig 9.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 123.5 KB - MD5: bca376270d42ef0d17b56dc422bd4937
Suppl. Fig. 9. Forest plot for subgroups of ICI types trials investigating hyperthyroidism grade 3-5 under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 8.pdf
Vardarli_Suppl Fig 8.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 80.8 KB - MD5: 57e8d84f42b25d9f50320342f7c3ccee
Suppl. Fig. 8. Forest plot for cumulative meta-analysis for trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl Fig 7.pdf
Vardarli_Suppl Fig 7.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 124.3 KB - MD5: 529ade845823207e4f85f60a376b1ace
Suppl. Fig. 7. Forest plot for subgroups of ICI types trials investigating hyperthyroidism any grade under immune checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.